目的： 分析山东省2018—2022年18岁以上人群成人疫苗接种情况。 方法： 通过山东省预防接种信息系统，收集2022年全省预防接种单位数据及2018—2022年间18周岁以上人群疫苗接种信息个案，描述性分析成人疫苗接种单位的分布和成人接种疫苗品种，计算接种总量及接种率。 结果： 2022年底，山东省共有提供成人疫苗接种的预防接种单位3 948家，每万人拥有成人预防接种门诊0.36家。2018—2022年，开展了人用狂犬病疫苗（RabV）、流感疫苗（InfV）、人乳头瘤病毒（HPV）疫苗、乙型肝炎疫苗（HepB）、23价肺炎球菌多糖疫苗（PPV23）、ACYW135群脑膜炎球菌多糖疫苗（MenACYW135）、麻疹-风疹-流行性腮腺炎联合减毒活疫苗（MMR）、戊型肝炎疫苗（HepE）、重组带状疱疹疫苗（RZV）、破伤风疫苗（TV）、流行性出血热（HF）疫苗共计11类成人疫苗的接种，接种总量为4 005.69万剂，平均0.1剂/（人·年）；RabV、InfV、HPV疫苗分别占接种总量的31.48%、22.57%和15.93%。2018—2022年，成人疫苗年均增长率为56.55%；RabV 和TV5年累计接种剂次分别为15.90剂/100人和0.21剂/100人；InfV年均接种率为2.28%；HPV疫苗、HepB、PPV23、RZV累计全程接种率分别为12.44%、1.61%、0.52%和0.17%。20~<30岁年龄组RabV和TV 5年累计接种剂次为29.19剂/100人和0.43剂/100人；70~<80岁年龄组InfV和 PPV23接种率分为9.08%和1.27%；50~<60岁年龄组RZV接种率为0.11%；20~<30岁年龄组HPV疫苗接种率为18.09%；18~19岁年龄组HepB、MenACYW135、MMR、HEV接种率分为6.21%、9.55%、2.65%和2.83%。 结论： 山东省成人疫苗接种品种较少，普及面窄，接种率较低。.

2023-05-01·PharmacoEconomics

Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella

Review

作者: van Hoek, Albert Jan ; Luyten, Jeroen ; Doggen, Kris

OBJECTIVESEconomic evaluations of vaccines should accurately represent all relevant economic and health consequences of vaccination, including losses due to adverse events following immunization (AEFI). We investigated to what extent economic evaluations of pediatric vaccines account for AEFI, which methods are used to do so and whether inclusion of AEFI is associated with study characteristics and the vaccine's safety profile.METHODSA systematic literature search (MEDLINE, EMBASE, Cochrane Systematic Reviews and Trials, Database of the Centre for Reviews and Dissemination of the University of York, EconPapers, Paediatric Economic Database Evaluation, Tufts New England Cost-Effectiveness Analysis Registry, Tufts New England Global Health CEA, International Network of Agencies for Health Technology Assessment Database) was performed for economic evaluations published between 2014 and 29 April 2021 (date of search) pertaining to the five groups of pediatric vaccines licensed in Europe and the United States since 1998: the human papillomavirus (HPV) vaccines, the meningococcal vaccines (MCV), the measles-mumps-rubella-varicella (MMRV) combination vaccines, the pneumococcal conjugate vaccines (PCV) and the rotavirus vaccines (RV). Rates of accounting for AEFI were calculated, stratified by study characteristics (e.g., region, publication year, journal impact factor, level of industry involvement) and triangulated with the vaccine's safety profile (Advisory Committee on Immunization Practices [ACIP] recommendations and information on safety-related product label changes). The studies accounting for AEFI were analyzed in terms of the methods used to account for both cost and effect implications of AEFI.RESULTSWe identified 112 economic evaluations, of which 28 (25%) accounted for AEFI. This proportion was significantly higher for MMRV (80%, four out of five evaluations), MCV (61%, 11 out of 18 evaluations) and RV (60%, nine out of 15 evaluations) compared to HPV (6%, three out of 53 evaluations) and PCV (5%, one out of 21 evaluations). No other study characteristics were associated with a study's likelihood of accounting for AEFI. Vaccines for which AEFI were more frequently accounted for also had a higher frequency of label changes and a higher level of attention to AEFI in ACIP recommendations. Nine studies accounted for both the cost and health implications of AEFI, 18 studies considered only costs and one only health outcomes. While the cost impact was usually estimated based on routine billing data, the adverse health impact of AEFI was usually estimated based on assumptions.DISCUSSIONAlthough (mild) AEFI were demonstrated for all five studied vaccines, only a quarter of reviewed studies accounted for these, mostly in an incomplete and inaccurate manner. We provide guidance on which methods to use to better quantify the impact of AEFI on both costs and health outcomes. Policymakers should be aware that the impact of AEFI on cost-effectiveness is likely to be underestimated in the majority of economic evaluations.

2023-03-01·Reviews in Medical Virology

Safety of varicella vaccination strategies: An overview of reviews

Review

作者: Browne, John ; Murphy, Aileen ; Walsh, Kieran A. ; Carrigan, Marie ; Teljeur, Conor ; Harrington, Patricia ; Ryan, Máirín ; Ahern, Susan ; Paone, Simona

AbstractThe safety of new vaccines under development as well as existing vaccines is a key priority for national and international public health agencies. A number of countries have implemented universal childhood varicella vaccination programmes over the past 30 years. However, strategies differ in terms of the number of doses, type of vaccine(s) recommended, age at vaccination and interval between doses for a two‐dose schedule. An overview of reviews was undertaken to assess the existing systematic review evidence of the safety of varicella vaccination strategies. The review was restricted to immunocompetent children aged 9 months to 6 years inclusive. A comprehensive search of databases, registries and grey literature was conducted up to 2 February 2022. Two reviewers independently screened, extracted data and assessed the methodological quality of included reviews. Overlap of included reviews was also assessed. A total of 17 reviews, incorporating both the monovalent varicella only and quadrivalent measles‐mumps‐rubella‐varicella (MMRV) vaccines were included in the overview; six assessed the safety of one‐dose strategies, four assessed the safety of two‐dose strategies and 14 reviews did not specify the dosing strategy. The evidence suggests that mild local and systemic reactions are relatively common with varicella vaccination. Febrile seizures are also possible adverse effects of both the monovalent and quadrivalent MMRV vaccine, but serious adverse reactions are rare. While most reviews contained methodological flaws, and analysis by vaccine type and dosing strategy was restricted due to lack of detail in reporting of the reviews, there was clear and consistent evidence from a substantial evidence base, comprising 34 randomised controlled trials and 62 other primary studies/reviews, that varicella vaccination is safe.

100 项与麻腮风联合减毒活疫苗 (北京天坛生物) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BD52	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
麻疹	中国	北京生物制品研究所有限责任公司	2002-01-01
流行性腮腺炎	中国	北京生物制品研究所有限责任公司	2002-01-01
腮腺炎病毒感染	中国	北京生物制品研究所有限责任公司	2002-01-01